Sarah C Mann1, Mary Morrow2, Ryan P Coyle1, Stacey S Coleman3, Austin Saderup4, Jia-Hua Zheng5, Lucas Ellison5, Lane R Bushman5, Jennifer J Kiser5, Samantha MaWhinney2, Peter L Anderson5, Jose R Castillo-Mancilla1. 1. Division of Infectious Diseases, School of Medicine, University of Colorado-AMC, Aurora, CO. 2. Department of Biostatistics and Bioinformatics, Colorado School of Public Health, Aurora, CO. 3. Duke University Hospital, Durham, NC. 4. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-AMC, Aurora, CO; and. 5. Colorado Antiviral Pharmacology Laboratory and Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-AMC, Aurora, CO.
Abstract
OBJECTIVE: People living with HIV (PLWH) are living longer and developing more non-AIDS comorbidities, which negatively impact antiretroviral therapy (ART) adherence. Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a novel pharmacologic measure of cumulative ART adherence that is predictive of viral suppression and future viremia. However, the relationship between non-AIDS comorbidities and this adherence measure is unknown. We aimed to evaluate the association between 3 non-AIDS comorbidities (diabetes mellitus (DM), hypertension, and hyperlipidemia) and TFV-DP in DBS in PLWH. METHODS: Blood for TFV-DP in DBS and HIV viral load was prospectively collected from PLWH on tenofovir disoproxil fumarate for up to 3 times over 48 weeks. Non-AIDS comorbidities were recorded. Mixed effect multivariable linear regression models were used to estimate the changes in TFV-DP concentrations in DBS according to the presence of comorbidities and to estimate the percent differences in TFV-DP concentrations between these groups. RESULTS: A total of 1144 person-visits derived from 523 participants with available concentrations of TFV-DP in DBS were included in this analysis. In univariate analysis, no significant association between non-AIDS comorbidities (categorized as having 0, 1, 2, or 3 comorbidities) and the concentrations of TFV-DP in DBS was observed (P = 0.40). Participants who had DM had 25% lower (95% confidence interval: -36% to -12%; P < 0.001) TFV-DP in DBS than participants without DM after adjusting for age, gender, race, body mass index, estimated glomerular filtration rate, CD4 T-cell count, hematocrit, ART class, patient-level medication regimen complexity index, and 3-month self-reported adherence. CONCLUSIONS: Diabetic PLWH have lower concentrations of TFV-DP in DBS compared with those without DM. Further research is required to identify the clinical implications and biological mechanisms underlying these findings.
OBJECTIVE: People living with HIV (PLWH) are living longer and developing more non-AIDS comorbidities, which negatively impact antiretroviral therapy (ART) adherence. Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a novel pharmacologic measure of cumulative ART adherence that is predictive of viral suppression and future viremia. However, the relationship between non-AIDS comorbidities and this adherence measure is unknown. We aimed to evaluate the association between 3 non-AIDS comorbidities (diabetes mellitus (DM), hypertension, and hyperlipidemia) and TFV-DP in DBS in PLWH. METHODS: Blood for TFV-DP in DBS and HIV viral load was prospectively collected from PLWH on tenofovir disoproxil fumarate for up to 3 times over 48 weeks. Non-AIDS comorbidities were recorded. Mixed effect multivariable linear regression models were used to estimate the changes in TFV-DP concentrations in DBS according to the presence of comorbidities and to estimate the percent differences in TFV-DP concentrations between these groups. RESULTS: A total of 1144 person-visits derived from 523 participants with available concentrations of TFV-DP in DBS were included in this analysis. In univariate analysis, no significant association between non-AIDS comorbidities (categorized as having 0, 1, 2, or 3 comorbidities) and the concentrations of TFV-DP in DBS was observed (P = 0.40). Participants who had DM had 25% lower (95% confidence interval: -36% to -12%; P < 0.001) TFV-DP in DBS than participants without DM after adjusting for age, gender, race, body mass index, estimated glomerular filtration rate, CD4 T-cell count, hematocrit, ART class, patient-level medication regimen complexity index, and 3-month self-reported adherence. CONCLUSIONS: Diabetic PLWH have lower concentrations of TFV-DP in DBS compared with those without DM. Further research is required to identify the clinical implications and biological mechanisms underlying these findings.
Authors: Jose R Castillo-Mancilla; Mary Morrow; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha Mawhinney; Peter L Anderson Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: H Takanaga; A Ohnishi; S Yamada; H Matsuo; S Morimoto; Y Shoyama; H Ohtani; Y Sawada Journal: J Pharmacol Exp Ther Date: 2000-04 Impact factor: 4.030
Authors: Sharon M Seifert; Jose R Castillo-Mancilla; Kristine M Erlandson; Peter L Anderson Journal: Expert Opin Drug Metab Toxicol Date: 2017-04-03 Impact factor: 4.481
Authors: C Adithan; G Sriram; R P Swaminathan; C H Shashindran; J S Bapna; M Krishnan; S Chandrasekar Journal: Int J Clin Pharmacol Ther Toxicol Date: 1989-10
Authors: Jia-Hua Zheng; Caitlin Rower; Kevin McAllister; Jose Castillo-Mancilla; Brandon Klein; Amie Meditz; L Anthony Guida; Jennifer J Kiser; Lane R Bushman; Peter L Anderson Journal: J Pharm Biomed Anal Date: 2016-01-21 Impact factor: 3.935
Authors: E Jennifer Edelman; Kirsha S Gordon; Janis Glover; Ian R McNicholl; David A Fiellin; Amy C Justice Journal: Drugs Aging Date: 2013-08 Impact factor: 3.923
Authors: Austin M Saderup; Mary Morrow; Anne M Libby; Ryan P Coyle; Stacey S Coleman; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson; Jose R Castillo-Mancilla Journal: Pharmacotherapy Date: 2021-01-09 Impact factor: 4.705